A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Abstract

BackgroundEscalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs). To date, no systematic assessment of the cost-effectiveness (CE) of ICIs has been performed.MethodsPRISMA-guided systematic searches of the PubMed database were conducted. Studies of head/neck (n = 3), lung (n = 5), genitourinary (n = 4), and melanoma (n = 8) malignancies treated with ICIs were evaluated. The reference willingness-to-pay (WTP) threshold was $100,000/QALY.ResultsNivolumab was not cost-effective over chemotherapy for recurrent/metastatic head/neck cancers (HNCs). For non-small cell lung cancer (NSCLC), nivolumab was not cost-effective for a general cohort, but increased PD-L1 cutoffs resulted in CE. Pembrolizumab was cost-effective for both previously treated and newly-diagnosed metastatic NSCLC. For genitourinary cancers (GUCs, renal cell and bladder cancers), nivolumab and pembrolizumab were not cost-effective options. Regarding metastatic/unresected melanoma, ipilimumab monotherapy is less cost-effective than nivolumab, nivolumab/ipilimumab, and pembrolizumab. The addition of ipilimumab to nivolumab monotherapy was not adequately cost-effective. Pembrolizumab or nivolumab monotherapy offered comparable CE profiles.ConclusionsWith limited data and from the reference WTP, nivolumab was not cost-effective for HNCs. Pembrolizumab was cost-effective for NSCLC; although not the case for nivolumab, applying PD-L1 cutoffs resulted in adequate CE. Most data for nivolumab and pembrolizumab in GUCs did not point towards adequate CE. Contrary to ipilimumab, either nivolumab or pembrolizumab is cost-effective for melanoma. Despite these conclusions, it cannot be overstated that careful patient selection is critical for CE. Future publication of CE investigations and clinical trials (along with longer follow-up of existing data) could substantially alter conclusions from this analysis.

Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans

“…The less common, but more serious form of bladder cancer consists of high-grade muscle-invasive urothelial carcinoma (InvUC). InvUC is associated with a 50% lethality rate, marked reduction in quality of life from the cancer and its treatment (cystectomy, radiation therapy, chemotherapy), and high medical costs ($150,000 to >$200,000 per patient) (4)(5)(6)(7)(8)(9)(10). In the last two to three decades, only modest improvement has occurred in the outcome of patients with InvUC.…”

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

“…However, real-world data had shown that even with the same treatment, due to individual characteristics, the therapeutic effect can be quite different among cancer patients with the same indication. Meanwhile, the high cost of checkpoint inhibitors greatly increases the financial burden on patients [6]. Therefore, researchers have conducted a large number of studies to explore factors affecting the efficacy of checkpoint inhibitors, aiming to provide a solid foundation in the selection of clinical treatment regimens.…”

Unemployment and health-related quality of life in melanoma patients during the COVID-19 pandemic: A web-based cross-sectional study

“…The disability-adjusted life-years (DALYs) of melanoma have been increasing in China during the last decade, while the DALYs of common cancers such as esophageal cancer and stomach cancer have decreased signi cantly [11]. In recent years, the development of immune therapy bene ts cancer patients substantially, but also leads to a heavy economic burden for them [13]. A review indicates that higher spending on cancer is consistently associated with lower mortality [14].…”